Literature DB >> 16982772

Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.

Dongpo Cai1, Vaughan M Latham, Xinxin Zhang, Geoffrey I Shapiro.   

Abstract

Selective cyclin-dependent kinase (cdk) 2 inhibition is readily compensated. However, reduced cdk2 activity may have antiproliferative effects in concert with other family members. Here, inducible RNA interference was used to codeplete cdk2 and cdk1 from NCI-H1299 non-small cell lung cancer and U2OS osteosarcoma cells, and effects were compared with those mediated by depletion of either cdk alone. Depletion of cdk2 slowed G1 progression of NCI-H1299 cells and depletion of cdk1 slowed G2-M progression in both cell lines, with associated endoreduplication in U2OS cells. However, compared with the incomplete cell cycle blocks produced by individual depletion, combined depletion had substantial consequences, with G2-M arrest predominating in NCI-H1299 cells and apoptosis the primary outcome in U2OS cells. In U2OS cells, combined depletion affected RNA polymerase II expression and phosphorylation, causing decreased expression of the antiapoptotic proteins Mcl-1 and X-linked inhibitor of apoptosis (XIAP), effects usually mediated by inhibition of the transcriptional cdk9. These events do not occur after individual depletion of cdk2 and cdk1, suggesting that reduction of cdk2, cdk1, and RNA polymerase II activities all contribute to apoptosis in U2OS cells. The limited cell death induced by combined depletion in NCI-H1299 cells was significantly increased by codepletion of cdk9 or XIAP or by simultaneous treatment with the cdk9 inhibitor flavopiridol. These results show the potency of concomitant compromise of cell cycle and transcriptional cdk activities and may guide the selection of clinical drug candidates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982772     DOI: 10.1158/0008-5472.CAN-06-1758

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

1.  The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells.

Authors:  Wei Fu; Le Ma; Baoky Chu; Xue Wang; Marilyn M Bui; Jennifer Gemmer; Soner Altiok; W Jackson Pledger
Journal:  Mol Cancer Ther       Date:  2011-04-13       Impact factor: 6.261

2.  Hematopoiesis and thymic apoptosis are not affected by the loss of Cdk2.

Authors:  Cyril Berthet; Maria Cecilia Rodriguez-Galan; Deborah L Hodge; John Gooya; Véronique Pascal; Howard A Young; Jonathan Keller; Remy Bosselut; Philipp Kaldis
Journal:  Mol Cell Biol       Date:  2007-05-07       Impact factor: 4.272

3.  The combined effect of encapsulating curcumin and C6 ceramide in liposomal nanoparticles against osteosarcoma.

Authors:  Santosh S Dhule; Patrice Penfornis; Jibao He; Michael R Harris; Treniece Terry; Vijay John; Radhika Pochampally
Journal:  Mol Pharm       Date:  2014-01-24       Impact factor: 4.939

4.  Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor.

Authors:  Makiko Kobayashi; Ikuko Takahashi-Suzuki; Toshiyasu Shimomura; Yoshikazu Iwasawa; Hiroshi Hirai
Journal:  Invest New Drugs       Date:  2010-06-04       Impact factor: 3.850

5.  Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.

Authors:  Kamil Paruch; Michael P Dwyer; Carmen Alvarez; Courtney Brown; Tin-Yau Chan; Ronald J Doll; Kerry Keertikar; Chad Knutson; Brian McKittrick; Jocelyn Rivera; Randall Rossman; Greg Tucker; Thierry Fischmann; Alan Hruza; Vincent Madison; Amin A Nomeir; Yaolin Wang; Paul Kirschmeier; Emma Lees; David Parry; Nicole Sgambellone; Wolfgang Seghezzi; Lesley Schultz; Frances Shanahan; Derek Wiswell; Xiaoying Xu; Quiao Zhou; Ray A James; Vidyadhar M Paradkar; Haengsoon Park; Laura R Rokosz; Tara M Stauffer; Timothy J Guzi
Journal:  ACS Med Chem Lett       Date:  2010-05-17       Impact factor: 4.345

6.  The formation of tight tumor clusters affects the efficacy of cell cycle inhibitors: a hybrid model study.

Authors:  Munju Kim; Damon Reed; Katarzyna A Rejniak
Journal:  J Theor Biol       Date:  2014-03-05       Impact factor: 2.691

7.  Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.

Authors:  Shao Xie; Hui Jiang; Xiao-Wen Zhai; Fan Wei; Shu-Dong Wang; Jian Ding; Yi Chen
Journal:  Acta Pharmacol Sin       Date:  2016-08-29       Impact factor: 6.150

Review 8.  Emerging drug profile: cyclin-dependent kinase inhibitors.

Authors:  James S Blachly; John C Byrd
Journal:  Leuk Lymphoma       Date:  2013-07-29

9.  The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.

Authors:  Paolo Bonvini; Elisa Zorzi; Lara Mussolin; Giovanni Monaco; Martina Pigazzi; Giuseppe Basso; Angelo Rosolen
Journal:  Haematologica       Date:  2009-06-16       Impact factor: 9.941

10.  Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.

Authors:  N Johnson; J Bentley; L-Z Wang; D R Newell; C N Robson; G I Shapiro; N J Curtin
Journal:  Br J Cancer       Date:  2009-12-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.